Intended Use

Jazz is intended for the labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images, for patients with a known diagnosis of multiple sclerosis (for the multiple sclerosis pipeline) and/or brain metastasis (for the metastasis pipeline), and the production of a radiological report.

Technology

Jazz is a Software as a Medical Device (SaMD) using semi-automatic processing pipelines for MR images. It performs image coregistration, contrast recognition, optional pre-annotation of abnormalities by various algorithms, and allows the physician to review and correct segmentations before finalizing the report. The software outputs radiological reports in formats like text, PDF, and DICOM.

Performance

The device performance was validated for accuracy and reproducibility against expert manual labeling on 344 subject datasets including healthy subjects, multiple sclerosis and metastasis patients. Accuracy acceptance criteria for sensitivity, specificity, lesion-wise dice scores, anatomy localization, and coregistration quality were met. Reproducibility was demonstrated with consistent lesion counts, volumes, and report generation in test-retest experiments. System verification confirmed device capabilities for its intended use.

Predicate Devices

No predicate devices specified

Device Timeline

  • 1

    Submission

    12/6/2022

    9 months
  • 2

    FDA Approval

    9/22/2023

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.